Related Experiment Video
Updated: Sep 9, 2025
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Association Between ABCB1 Gene Polymorphism with Hyperglycemia and MACE in Patients Undergoing Clopidogrel Treatment
Bo Zhou1, Chuanshen Shi2, Qike Xu1
1Clinical Pharmacy, The Affiliated Taian City Central Hospital of Qingdao University, Taian, Shandong, People's Republic of China.
Insights
The ABCB1 C3435T gene variant is a risk factor for major adverse cardiovascular events (MACE) in patients on clopidogrel after PCI. However, the ABCB1 CC genotype with normal blood sugar may offer protection in younger patients.
Area of Science:
- Cardiovascular Medicine
- Pharmacogenomics
- Genetics
Background:
- Clopidogrel is a widely used antiplatelet medication following percutaneous coronary intervention (PCI).
- Genetic variations, such as in the ABCB1 gene, can influence drug response and clinical outcomes.
- Hyperglycemia is a known risk factor for cardiovascular events.
Purpose of the Study:
- To investigate the association between the ABCB1 C3435T gene polymorphism, hyperglycemia, and the risk of major adverse cardiovascular events (MACE).
- To assess the impact of these factors on patients undergoing clopidogrel therapy post-PCI.
Main Methods:
- A cohort of 117 patients treated with clopidogrel after PCI was studied.
- ABCB1 C3435T genotypes were determined using fluorescence in situ hybridization.
- Logistic regression analysis identified independent risk factors for MACE, considering baseline characteristics, fasting blood glucose, and clinical outcomes.
Main Results:
- The ABCB1 C3435T genotype was identified as an independent risk factor for MACE (P=0.024, OR=5.584).
- Other independent MACE risk factors included age, history of hypertension, and history of diabetes mellitus.
- In patients under 75 years, the ABCB1 CC genotype combined with normoglycemia showed a protective effect against MACE (P=0.023, OR=0.147).
Conclusions:
- The ABCB1 C3435T genotype is a significant independent risk factor for MACE in patients receiving clopidogrel therapy after PCI.
- The combination of the ABCB1 CC genotype and normoglycemia may confer a protective effect against MACE in patients younger than 75 years.
Purpose:
To evaluate the effect of ABCB1 C3435T gene polymorphism with hyperglycemia on the risk of major adverse cardiovascular events (MACE) in patients treated with clopidogrel after percutaneous coronary intervention (PCI).
Patients And Methods:
A total of 117 patients were studied, of which 52 developed MACE. We used fluorescence in situ hybridization to detect the genotype of the CYP2C19 and ABCB1 C3435T loci. Baseline characteristics, fasting blood glucose, and clinical outcomes were collected. Logistic regression was used to analyze factors influencing MACE in PCI patients treated with clopidogrel.
Results:
There were significant differences between normal and MACE groups in gender, age, history of diabetes mellitus, history of alcohol consumption, fasting blood glucose, ABCB1 (CC) with normoglycemia, and ABCB1 (CT/TT) combined with hyperglycemia (P < 0.05). ABCB1 C3435T genotype (P= 0.024, OR = 5.584, 95% CI 1.258-24.780), age (P= 0.014, OR = 1.073, 95% CI 1.014-1.135), History of hypertension (P= 0.020, OR = 3.144, 95% CI 1.200-8.238) and History of diabetes mellitus (P= 0.030, OR = 3.731, 95% CI 1.135-12.270) were independent MACE risk factors. In patients <75 years, history of hypertension (P= 0.021, OR = 3.151, 95% CI 1.189-8.350) was a risk factor, while the ABCB1 (CC) with normoglycaemia (P= 0.023, OR = 0.147, 95% CI 0.028-0.767) was a protective factor.
Conclusion:
The ABCB1 C3435T genotype is an independent risk factor for MACE after PCI with clopidogrel therapy. ABCB1 CC combined normoglycemia may protect against MACE in patients <75 years.
Trial Registration:
Registration number: ChiCTR2400082012, Reg Date: 2024-03-19.
More Related Videos
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Coronary Artery Disease IV: Preventive Measures
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:27Coronary Artery Disease V: Interprofessional Care
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...